Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 2, 2015, Pages 211-225

  Chugh, Seema ^a   Gnanapragassam, Vinayaga S ^a   Jain, Maneesh ^a,b   Rachagani, Satyanarayana ^a   Ponnusamy, Moorthy P ^a,b   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer; Carbohydrate antigen; Glycan; Glycosyltransferase; Mucin; O glycosylation

Indexed keywords

GALECTIN; GLYCAN; GLYCOSIDASE; GLYCOSYLTRANSFERASE; GLYCOSYLTRANSFERASE INHIBITOR; MUCIN; NUCLEOTIDE TRANSPORTER; PEPTIDE VACCINE; SELECTIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; POLYSACCHARIDE; TUMOR MARKER;

CANCER GROWTH; CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL INTERACTION; ENZYME LOCALIZATION; GENE; GLYCOGENE; HUMAN; HYPOXIA; IMMUNOSURVEILLANCE; INFLAMMATION; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MOLECULAR WEIGHT; NEOPLASM; NONHUMAN; PH; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; ANIMAL; BIOLOGICAL MODEL; METABOLISM; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; BIOMARKERS, TUMOR; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; MOLECULAR TARGETED THERAPY; MUCINS; NEOPLASMS; POLYSACCHARIDES;

EID: 84941285571     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.08.003     Document Type: Review

References (172)

1. Kufe D.W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 2009, 9:874-885.
2. Rachagani S., Torres M.P., Moniaux N., Batra S.K. Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009, 35:509-527.
3. Johansson M.E., Sjovall H., Hansson G.C. The gastrointestinal mucus system in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:352-361.
4. Perez-Vilar J., Hill R.L. The structure and assembly of secreted mucins. J. Biol. Chem. 1999, 274:31751-31754.
5. Hattrup C.L., Gendler S.J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70:431-457.
6. Hollingsworth M.A., Swanson B.J. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004, 4:45-60.
7. Cullen P.J. Post-translational regulation of signaling mucins. Curr. Opin. Struct. Biol. 2011, 21:590-596.
8. Van Klinken B.J., Van der Wal J.W., Einerhand A.W., Buller H.A., Dekker J. Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcerative colitis. Gut 1999, 44:387-393.
9. Stanley P. Golgi glycosylation. Cold Spring Harb. Perspect. Biol. 2011, 3:a005199.
10. Van den Steen P., Rudd P.M., Dwek R.A., Opdenakker G. Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol. 1998, 33:151-208.
11. Stanley P., Schachter H., Taniguchi N. Chapter 8 N-Glycans. Essentials of Glycobiology 2009, 2nd edition.
12. Rose M.C., Voynow J.A. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol. Rev. 2006, 86:245-278.
13. Kaur S., Kumar S., Momi N., Sasson A.R., Batra S.K. Mucins in pancreatic cancer and its microenvironment. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:607-620.
14. Resto V.A., Burdick M.M., Dagia N.M., McCammon S.D., Fennewald S.M., Sackstein R. L-selectin-mediated lymphocyte-cancer cell interactions under low fluid shear conditions. J. Biol. Chem. 2008, 283:15816-15824.
15. Kornfeld R., Kornfeld S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54:631-664.
16. Brockhausen I., Schachte H., Stanley P. Chapter 9 O-GalNAc Glycans. Essentials of Glycobiology 2009, 2nd edition.
17. Schwarz F., Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol. 2011, 21:576-582.
18. Ruddock L.W., Molinari M. N-glycan processing in ER quality control. J. Cell Sci. 2006, 119:4373-4380.
19. Parry S., Hanisch F.G., Leir S.H., Sutton-Smith M., Morris H.R., Dell A., Harris A. N-glycosylation of the MUC1 mucin in epithelial cells and secretions. Glycobiology 2006, 16:623-634.
20. Cao R., Wang T.T., DeMaria G., Sheehan J.K., Kesimer M. Mapping the protein domain structures of the respiratory mucins: a mucin proteome coverage study. J. Proteome Res. 2012, 11:4013-4023.
21. Asker N., Axelsson M.A., Olofsson S.O., Hansson G.C. Dimerization of the human MUC2 mucin in the endoplasmic reticulum is followed by a N-glycosylation-dependent transfer of the mono- and dimers to the Golgi apparatus. J. Biol. Chem. 1998, 273:18857-18863.
22. Ambort D., Johansson M.E., Gustafsson J.K., Nilsson H.E., Ermund A., Johansson B.R., Koeck P.J., Hebert H., Hansson G.C. Calcium and pH-dependent packing and release of the gel-forming MUC2 mucin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5645-5650.
23. Backstrom M., Ambort D., Thomsson E., Johansson M.E., Hansson G.C. Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains. Mol. Biotechnol. 2013, 54:250-256.
24. Ho J.J., Jaituni R.S., Crawley S.C., Yang S.C., Gum J.R., Kim Y.S. N-glycosylation is required for the surface localization of MUC17 mucin. Int. J. Oncol. 2003, 23:585-592.
25. Marth J.D. Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Glycobiology 1996, 6:701-705.
26. Bennett E.P., Mandel U., Clausen H., Gerken T.A., Fritz T.A., Tabak L.A. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology 2012, 22:736-756.
27. Ju T., Otto V.I., Cummings R.D. The Tn antigen-structural simplicity and biological complexity. Angew. Chem. Int. Ed. Engl. 2011, 50:1770-1791.
28. Yoshida A., Suzuki M., Ikenaga H., Takeuchi M. Discovery of the shortest sequence motif for high level mucin-type O-glycosylation. J. Biol. Chem. 1997, 272:16884-16888.
29. Kinarsky L., Suryanarayanan G., Prakash O., Paulsen H., Clausen H., Hanisch F.G., Hollingsworth M.A., Sherman S. Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. Glycobiology 2003, 13:929-939.
30. Raman J., Fritz T.A., Gerken T.A., Jamison O., Live D., Liu M., Tabak L.A. The catalytic and lectin domains of UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferase function in concert to direct glycosylation site selection. J. Biol. Chem. 2008, 283:22942-22951.
31. Aryal R.P., Ju T., Cummings R.D. The endoplasmic reticulum chaperone Cosmc directly promotes in vitro folding of T-synthase. J. Biol. Chem. 2010, 285:2456-2462.
32. Ju T., Aryal R.P., Kudelka M.R., Wang Y., Cummings R.D. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark. 2014, 14:63-81.
33. Tran D.T., Ten Hagen K.G. Mucin-type O-glycosylation during development. J. Biol. Chem. 2013, 288:6921-6929.
34. Ho J.J., Siddiki B., Kim Y.S. Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin in a pancreatic cancer cell line. Cancer Res. 1995, 55:3659-3663.
35. Hauselmann I., Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front. Oncol. 2014, 4:28.
36. Julien S., Videira P.A., Delannoy P. Sialyl-tn in cancer: (how) did we miss the target?. Biomolecules. 2012, 2:435-466.
37. Engelmann K., Baldus S.E., Hanisch F.G. Identification and topology of variant sequences within individual repeat domains of the human epithelial tumor mucin MUC1. J. Biol. Chem. 2001, 276:27764-27769.
38. Linden S.K., Sutton P., Karlsson N.G., Korolik V., McGuckin M.A. Mucins in the mucosal barrier to infection. Mucosal Immunol. 2008, 1:183-197.
39. Robbe C., Capon C., Maes E., Rousset M., Zweibaum A., Zanetta J.P., Michalski J.C. Evidence of regio-specific glycosylation in human intestinal mucins: presence of an acidic gradient along the intestinal tract. J. Biol. Chem. 2003, 278:46337-46348.
40. Corfield A.P. Mucins: a biologically relevant glycan barrier in mucosal protection. Biochim. Biophys. Acta 2015, 1850:236-252.
41. Bafna S., Kaur S., Batra S.K. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010, 29:2893-2904.
42. Kufe D.W. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013, 32:1073-1081.
43. Mukhopadhyay P., Chakraborty S., Ponnusamy M.P., Lakshmanan I., Jain M., Batra S.K. Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. Biochim. Biophys. Acta 2011, 1815:224-240.
44. Deng J., Wang L., Chen H., Li L., Ma Y., Ni J., Li Y. The role of tumor-associated MUC1 in epithelial ovarian cancer metastasis and progression. Cancer Metastasis Rev. 2013, 32:535-551.
45. Hinoda Y., Ikematsu Y., Horinochi M., Sato S., Yamamoto K., Nakano T., Fukui M., Suehiro Y., Hamanaka Y., Nishikawa Y., Kida H., Waki S., Oka M., Imai K., Yonezawa S. Increased expression of MUC1 in advanced pancreatic cancer. J. Gastroenterol. 2003, 38:1162-1166.
46. Wang R.Q., Fang D.C. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J. Clin. Pathol. 2003, 56:378-384.
47. Bafna S., Kaur S., Momi N., Batra S.K. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin. Br. J. Cancer 2009, 101:1155-1161.
48. Mukhopadhyay P., Lakshmanan I., Ponnusamy M.P., Chakraborty S., Jain M., Pai P., Smith L.M., Lele S.M., Batra S.K. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells. PLoS ONE 2013, 8.
49. Rachagani S., Macha M.A., Ponnusamy M.P., Haridas D., Kaur S., Jain M., Batra S.K. MUC4 potentiates invasion and metastasis of pancreatic cancer cells through stabilization of fibroblast growth factor receptor 1. Carcinogenesis 2012, 33:1953-1964.
50. Ponnusamy M.P., Seshacharyulu P., Vaz A., Dey P., Batra S.K. MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells. J. Ovarian Res. 2011, 4. 7.
51. Chaturvedi P., Singh A.P., Chakraborty S., Chauhan S.C., Bafna S., Meza J.L., Singh P.K., Hollingsworth M.A., Mehta P.P., Batra S.K. MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res. 2008, 68:2065-2070.
52. Haridas D., Ponnusamy M.P., Chugh S., Lakshmanan I., Seshacharyulu P., Batra S.K. MUC16: molecular analysis and its functional implications in benign and malignant conditions. FASEB J. 2014, 10:4183-4199.
53. Gubbels J.A., Felder M., Horibata S., Belisle J.A., Kapur A., Holden H., Petrie S., Migneault M., Rancourt C., Connor J.P., Patankar M.S. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol. Cancer 2010, 9:11.
54. Theriault C., Pinard M., Comamala M., Migneault M., Beaudin J., Matte I., Boivin M., Piche A., Rancourt C. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol. Oncol. 2011, 121:434-443.
55. Haridas D., Chakraborty S., Ponnusamy M.P., Lakshmanan I., Rachagani S., Cruz E., Kumar S., Das S., Lele S.M., Anderson J.M., Wittel U.A., Hollingsworth M.A., Batra S.K. Pathobiological implications of MUC16 expression in pancreatic cancer. PLoS ONE 2011, 6.
56. Lakshmanan I., Ponnusamy M.P., Das S., Chakraborty S., Haridas D., Mukhopadhyay P., Lele S.M., Batra S.K. MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells. Oncogene 2012, 31:805-817.
57. Chen S.H., Hung W.C., Wang P., Paul C., Konstantopoulos K. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci. Rep. 2013, 3:1870.
58. Maher D.M., Gupta B.K., Nagata S., Jaggi M., Chauhan S.C. Mucin 13: structure, function, and potential roles in cancer pathogenesis. Mol. Cancer Res. 2011, 9:531-537.
59. Hoshi H., Sawada T., Uchida M., Saito H., Iijima H., Toda-Agetsuma M., Wada T., Yamazoe S., Tanaka H., Kimura K., Kakehashi A., Wei M., Hirakawa K., Wanibuchi H. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int. J. Oncol. 2011, 38:619-627.
60. Walsh M.D., Clendenning M., Williamson E., Pearson S.A., Walters R.J., Nagler B., Packenas D., Win A.K., Hopper J.L., Jenkins M.A., Haydon A.M., Rosty C., English D.R., Giles G.G., McGuckin M.A., Young J.P., Buchanan D.D. Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod. Pathol. 2013, 26:1642-1656.
61. Kawashima H. Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. Biol. Pharm. Bull. 2012, 35:1637-1641.
62. Pan S., Chen R., Tamura Y., Crispin D.A., Lai L.A., May D.H., McIntosh M.W., Goodlett D.R., Brentnall T.A. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J. Proteome Res. 2014, 13:1293-1306.
63. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim. Biophys. Acta 1999, 1473:67-95.
64. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10231-10233.
65. Robbe-Masselot C., Maes E., Rousset M., Michalski J.C., Capon C. Glycosylation of human fetal mucins: a similar repertoire of O-glycans along the intestinal tract. Glycoconj. J. 2009, 26:397-413.
66. Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1999, 1455:301-313.
67. Campbell B.J., Finnie I.A., Hounsell E.F., Rhodes J.M. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J. Clin. Invest. 1995, 95:571-576.
68. Klein A., Roussel P. O-acetylation of sialic acids. Biochimie 1998, 80:49-57.
69. Corfield A.P., Myerscough N., Warren B.F., Durdey P., Paraskeva C., Schauer R. Reduction of sialic acid O-acetylation in human colonic mucins in the adenoma-carcinoma sequence. Glycoconj. J. 1999, 16:307-317.
70. Danguy A., Camby I., Kiss R. Galectins and cancer. Biochim. Biophys. Acta 2002, 1572:285-293.
71. van den Brule F., Califice S., Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj. J. 2004, 19:537-542.
72. Rabinovich G.A., Rubinstein N., Toscano M.A. Role of galectins in inflammatory and immunomodulatory processes. Biochim. Biophys. Acta 2002, 1572:274-284.
73. Zhao Q. Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface 2009, 6799-6806. 69.
74. Thijssen V.L., Postel R., Brandwijk R.J., Dings R.P., Nesmelova I., Satijn S., Verhofstad N., Nakabeppu Y., Baum L.G., Bakkers J., Mayo K.H., Poirier F., Griffioen A.W. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15975-15980.
75. Hsu Y.L., Wu C.Y., Hung J.Y., Lin Y.S., Huang M.S., Kuo P.L. Galectin-1 promotes lung cancer tumor metastasis by potentiating integrin alpha6beta4 and Notch1/Jagged2 signaling pathway. Carcinogenesis 2013, 34:1370-1381.
76. Argueso P., Guzman-Aranguez A., Mantelli F., Cao Z., Ricciuto J., Panjwani N. Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J. Biol. Chem. 2009, 284:23037-23045.
77. Kansas G.S. Selectins and their ligands: current concepts and controversies. Blood 1996, 88:3259-3287.
78. Byrd J.C., Bresalier R.S. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004, 23:77-99.
79. Kim Y.J., Borsig L., Han H.L., Varki N.M., Varki A. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am. J. Pathol. 1999, 155:461-472.
80. Wahrenbrock M., Borsig L., Le D., Varki N., Varki A. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J. Clin. Invest. 2003, 112:853-862.
81. Crocker P.R. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. 2002, 12:609-615.
82. Crocker P.R., Paulson J.C., Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 2007, 7:255-266.
83. Nath D., Hartnell A., Happerfield L., Miles D.W., Burchell J., Taylor-Papadimitriou J., Crocker P.R. Macrophage-tumour cell interactions: identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunology 1999, 98:213-219.
84. Tanida S., Akita K., Ishida A., Mori Y., Toda M., Inoue M., Ohta M., Yashiro M., Sawada T., Hirakawa K., Nakada H. Binding of the sialic acid-binding lectin, Siglec-9, to the membrane mucin, MUC1, induces recruitment of beta-catenin and subsequent cell growth. J. Biol. Chem. 2013, 288:31842-31852.
85. Belisle J.A., Horibata S., Jennifer G.A., Petrie S., Kapur A., Andre S., Gabius H.J., Rancourt C., Connor J., Paulson J.C., Patankar M.S. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol. Cancer 2010, 9:118-119.
86. Costello R.T., Gastaut J.A., Olive D. Tumor escape from immune surveillance. Arch. Immunol. Ther. Exp. 1999, 47:83-88.
87. Madsen C.B., Lavrsen K., Steentoft C., Vester-Christensen M.B., Clausen H., Wandall H.H., Pedersen A.E. Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing. PLoS ONE 2013, 8.
88. Vanharanta S., Massague J. Origins of metastatic traits. Cancer Cell 2013, 24:410-421.
89. Havrylov S., Redowicz M.J., Buchman V.L. Emerging roles of Ruk/CIN85 in vesicle-mediated transport, adhesion, migration and malignancy. Traffic 2010, 11:721-731.
90. Cascio S., Farkas A.M., Hughey R.P., Finn O.J. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget 2013, 4:1686-1697.
91. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3352-3357.
92. Senapati S., Chaturvedi P., Chaney W.G., Chakraborty S., Gnanapragassam V.S., Sasson A.R., Batra S.K. Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin. Cancer Res. 2011, 17:267-274.
93. Yu L.G., Andrews N., Zhao Q., McKean D., Williams J.F., Connor L.J., Gerasimenko O.V., Hilkens J., Hirabayashi J., Kasai K., Rhodes J.M. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer-associated MUC1 causes increased cancer cell endothelial adhesion. J. Biol. Chem. 2007, 282:773-781.
94. Zhao Q., Barclay M., Hilkens J., Guo X., Barrow H., Rhodes J.M., Yu L.G. Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis. Mol. Cancer 2010, 9:154-166.
95. Gubbels J.A., Belisle J., Onda M., Rancourt C., Migneault M., Ho M., Bera T.K., Connor J., Sathyanarayana B.K., Lee B., Pastan I., Patankar M.S. Mesothelin-MUC16 binding is a high affinity N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol. Cancer 2006, 5:50.
96. Kinlough C.L., Poland P.A., Gendler S.J., Mattila P.E., Mo D., Weisz O.A., Hughey R.P. Core-glycosylated mucin-like repeats from MUC1 are an apical targeting signal. J. Biol. Chem. 2011, 286:39072-39081.
97. Prescher J.A., Bertozzi C.R. Chemical technologies for probing glycans. Cell 2006, 126:851-854.
98. Potter B.A., Hughey R.P., Weisz O.A. Role of N- and O-glycans in polarized biosynthetic sorting. Am. J. Physiol Cell Physiol. 2006, 290:C1-C10.
99. Paszkiewicz-Gadek A., Porowska H., Lemancewicz D., Wolczynski S., Gindzienski A. The influence of N- and O-glycosylation inhibitors on the glycosylation profile of cellular membrane proteins and adhesive properties of carcinoma cell lines. Int. J. Mol. Med. 2006, 17:669-674.
100. Engelmann K., Kinlough C.L., Muller S., Razawi H., Baldus S.E., Hughey R.P., Hanisch F.G. Transmembrane and secreted MUC1 probes show trafficking-dependent changes in O-glycan core profiles. Glycobiology 2005, 15:1111-1124.
101. Engelmann K., Shen H., Finn O.J. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 2008, 68:2419-2426.
102. Varki A. Factors controlling the glycosylation potential of the Golgi apparatus. Trends Cell Biol. 1998, 8:34-40.
103. Rini J., Esko J., Varki A. Glycosyltransferases and glycan-processing enzymes. Essentials of Glycobiology 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY), (Chapter 5. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1921/). 2nd edition. A. Varki, R.D. Cummings, J.D. Esko (Eds.).
104. Ohtsubo K., Marth J.D. Glycosylation in cellular mechanisms of health and disease. Cell 2006, 126:855-867.
105. Kannagi R., Sakuma K., Miyazaki K., Lim K.T., Yusa A., Yin J., Izawa M. Altered expression of glycan genes in cancers induced by epigenetic silencing and tumor hypoxia: clues in the ongoing search for new tumor markers. Cancer Sci. 2010, 101:586-593.
106. Maupin K.A., Sinha A., Eugster E., Miller J., Ross J., Paulino V., Keshamouni V.G., Tran N., Berens M., Webb C., Haab B.B. Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems. PLoS ONE 2010, 5.
107. Kalthoff H., Kreiker C., Schmiegel W.H., Greten H., Thiele H.G. Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res. 1986, 46:3605-3607.
108. Miyazaki K., Ohmori K., Izawa M., Koike T., Kumamoto K., Furukawa K., Ando T., Kiso M., Yamaji T., Hashimoto Y., Suzuki A., Yoshida A., Takeuchi M., Kannagi R. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 2004, 64:4498-4505.
109. Iwai T., Kudo T., Kawamoto R., Kubota T., Togayachi A., Hiruma T., Okada T., Kawamoto T., Morozumi K., Narimatsu H. Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4572-4577.
110. Kawamura Y.I., Toyota M., Kawashima R., Hagiwara T., Suzuki H., Imai K., Shinomura Y., Tokino T., Kannagi R., Dohi T. DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. Gastroenterology 2008, 135:142-151.
111. Groux-Degroote S., Wavelet C., Krzewinski-Recchi M.A., Portier L., Mortuaire M., Mihalache A., Trinchera M., Delannoy P., Malagolini N., Chiricolo M., Dall'Olio F., Harduin-Lepers A. B4GALNT2 gene expression controls the biosynthesis of Sda and sialyl Lewis X antigens in healthy and cancer human gastrointestinal tract. Int. J. Biochem. Cell Biol. 2014, 53:442-449.
112. Malagolini N., Dall'Olio F., Di S.G., Minni F., Marrano D., Serafini-Cessi F. Expression of UDP-GalNAc:NeuAc alpha 2,3Gal beta-R beta 1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas. Cancer Res. 1989, 49:6466-6470.
113. Dohi T., Kawamura Y.I. Incomplete synthesis of the Sda/Cad blood group carbohydrate in gastrointestinal cancer. Biochim. Biophys. Acta 2008, 1780:467-471.
114. Kawamura Y.I., Kawashima R., Fukunaga R., Hirai K., Toyama-Sorimachi N., Tokuhara M., Shimizu T., Dohi T. Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. Cancer Res. 2005, 65:6220-6227.
115. Keita M., Wang Z.Q., Pelletier J.F., Bachvarova M., Plante M., Gregoire J., Renaud M.C., Mes-Masson A.M., Paquet E.R., Bachvarov D. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol. Oncol. 2013, 128:356-363.
116. Wang Z.Q., Bachvarova M., Morin C., Plante M., Gregoire J., Renaud M.C., Sebastianelli A., Bachvarov D. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget 2014, 5:544-560.
117. Gaziel-Sovran A., Segura M.F., Di M.R., Collins M.K., Hanniford D., Vega-Saenz de M.E., Rakus J.F., Dankert J.F., Shang S., Kerbel R.S., Bhardwaj N., Shao Y., Darvishian F., Zavadil J., Erlebacher A., Mahal L.K., Osman I., Hernando E. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011, 20:104-118.
118. Tu L., Banfield D.K. Localization of Golgi-resident glycosyltransferases. Cell. Mol. Life Sci. 2010, 67:29-41.
119. Munro S. An investigation of the role of transmembrane domains in Golgi protein retention. EMBO J. 1995, 14:4695-4704.
120. Pokrovskaya I.D., Willett R., Smith R.D., Morelle W., Kudlyk T., Lupashin V.V. Conserved oligomeric Golgi complex specifically regulates the maintenance of Golgi glycosylation machinery. Glycobiology 2011, 21:1554-1569.
121. Jackson C.L. Mechanisms of transport through the Golgi complex. J. Cell Sci. 2009, 122:443-452.
122. Patterson G.H., Hirschberg K., Polishchuk R.S., Gerlich D., Phair R.D., Lippincott-Schwartz J. Transport through the Golgi apparatus by rapid partitioning within a two-phase membrane system. Cell 2008, 133:1055-1067.
123. Dall'Olio F., Malagolini N., Trinchera M., Chiricolo M. Mechanisms of cancer-associated glycosylation changes. Front. Biosci. (Landmark. Ed) 2012, 17:670-699.
124. Freeze H.H., Elbein A.D. Glycosylation Precursors. Essentials of Glycobiology 2009, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (NY), (Chapter 4. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1929/). 2nd edition. A. Varki, R.D. Cummings, J.D. Esko (Eds.).
125. Kumamoto K., Goto Y., Sekikawa K., Takenoshita S., Ishida N., Kawakita M., Kannagi R. Increased expression of UDP-galactose transporter messenger RNA in human colon cancer tissues and its implication in synthesis of Thomsen-Friedenreich antigen and sialyl Lewis A/X determinants. Cancer Res. 2001, 61:4620-4627.
126. Yusa A., Miyazaki K., Kimura N., Izawa M., Kannagi R. Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells. Cancer Res. 2010, 70:4064-4073.
127. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
128. Koike T., Kimura N., Miyazaki K., Yabuta T., Kumamoto K., Takenoshita S., Chen J., Kobayashi M., Hosokawa M., Taniguchi A., Kojima T., Ishida N., Kawakita M., Yamamoto H., Takematsu H., Suzuki A., Kozutsumi Y., Kannagi R. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8132-8137.
129. Yin J., Hashimoto A., Izawa M., Miyazaki K., Chen G.Y., Takematsu H., Kozutsumi Y., Suzuki A., Furuhata K., Cheng F.L., Lin C.H., Sato C., Kitajima K., Kannagi R. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res. 2006, 66:2937-2945.
130. Banda K., Gregg C.J., Chow R., Varki N.M., Varki A. Metabolism of vertebrate amino sugars with N-glycolyl groups: mechanisms underlying gastrointestinal incorporation of the non-human sialic acid xeno-autoantigen N-glycolylneuraminic acid. J. Biol. Chem. 2012, 287:28852-28864.
131. Brinkman-Van der Linden E.C., Sjoberg E.R., Juneja L.R., Crocker P.R., Varki N., Varki A. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. J. Biol. Chem 2000, 275:8633-8640.
132. Ota H., Nakayama J., Momose M., Hayama M., Akamatsu T., Katsuyama T., Graham D.Y., Genta R.M. Helicobacter pylori infection produces reversible glycosylation changes to gastric mucins. Virchows Arch. 1998, 433:419-426.
133. Dube D.H., Bertozzi C.R. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat. Rev. Drug Discov. 2005, 4:477-488.
134. Campbell B.J., Yu L.G., Rhodes J.M. Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj. J. 2001, 18:851-858.
135. Renkonen J., Tynninen O., Hayry P., Paavonen T., Renkonen R. Glycosylation might provide endothelial zip codes for organ-specific leukocyte traffic into inflammatory sites. Am. J. Pathol. 2002, 161:543-550.
136. Lowe J.B. Glycan-dependent leukocyte adhesion and recruitment in inflammation. Curr. Opin. Cell Biol. 2003, 15:531-538.
137. Larsson J.M., Karlsson H., Crespo J.G., Johansson M.E., Eklund L., Sjovall H., Hansson G.C. Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm. Bowel Dis. 2011, 17:2299-2307.
138. Wu Y.M., Nowack D.D., Omenn G.S., Haab B.B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J. Proteome Res. 2009, 8:1876-1886.
139. Kreisman L.S., Cobb B.A. Infection, inflammation and host carbohydrates: a Glyco-evasion hypothesis. Glycobiology 2012, 22:1019-1030.
140. Barasch J., Kiss B., Prince A., Saiman L., Gruenert D., a-lAwqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991, 352:70-73.
141. Kellokumpu S., Sormunen R., Kellokumpu I. Abnormal glycosylation and altered Golgi structure in colorectal cancer: dependence on intra-Golgi pH. FEBS Lett. 2002, 516:217-224.
142. Rivinoja A., Kokkonen N., Kellokumpu I., Kellokumpu S. Elevated Golgi pH in breast and colorectal cancer cells correlates with the expression of oncofetal carbohydrate T-antigen. J. Cell. Physiol. 2006, 208:167-174.
143. Chandrasekaran E.V., Xue J., Xia J., Locke R.D., Patil S.A., Neelamegham S., Matta K.L. Characterization of cancer associated mucin type O-glycans using the exchange sialylation properties of mammalian sialyltransferase ST3Gal-II. J. Proteome Res. 2012, 11:2609-2618.
144. Tuccillo F.M., de L.A., Palmieri C., Fiume G., Bonelli P., Borrelli A., Tassone P., Scala I., Buonaguro F.M., Quinto I., Scala G. Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed. Res. Int. 2014, 2014:742831.
145. Peracaula R., Barrabes S., Sarrats A., Rudd P.M., de L.R. Altered glycosylation in tumours focused to cancer diagnosis. Dis. Markers 2008, 25:207-218.
146. Adamczyk B., Tharmalingam T., Rudd P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 2012, 1820:1347-1353.
147. Felder M., Kapur A., Gonzalez-Bosquet J., Horibata S., Heintz J., Albrecht R., Fass L., Kaur J., Hu K., Shojaei H., Whelan R.J., Patankar M.S. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol. Cancer 2014, 13:129.
148. Soletormos G., Nielsen D., Schioler V., Mouridsen H., Dombernowsky P. Monitoring different stages of breast cancer using tumour markers CA 15-3 CEA and TPA. Eur. J. Cancer 2004, 40:481-486.
149. Safi F., Schlosser W., Kolb G., Beger H.G. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J. Gastrointest. Surg. 1997, 1:106-112.
150. Ychou M., Duffour J., Kramar A., Gourgou S., Grenier J. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis. Markers 2000, 16:105-110.
151. Wahrenbrock M.G., Varki A. Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"?. Cancer Res. 2006, 66:2433-2441.
152. Wandall H.H., Blixt O., Tarp M.A., Pedersen J.W., Bennett E.P., Mandel U., Ragupathi G., Livingston P.O., Hollingsworth M.A., Taylor-Papadimitriou J., Burchell J., Clausen H. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010, 70:1306-1313.
153. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., Poulsen S.S., Pedersen A.E., Rasmussen S., Jess P., Clausen H., Wandall H.H. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128:1860-1871.
154. Pinto R., Carvalho A.S., Conze T., Magalhaes A., Picco G., Burchell J.M., Taylor-Papadimitriou J., Reis C.A., Almeida R., Mandel U., Clausen H., Soderberg O., David L. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J. Cell. Mol. Med. 2012, 16:1474-1484.
155. Guo Z., Wang Q. Recent development in carbohydrate-based cancer vaccines. Curr. Opin. Chem. Biol. 2009, 13:608-617.
156. Miles D., Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin. Breast Cancer 2003, 3(Suppl. 4):S134-S138.
157. Ibrahim N.K., Murray J.L. Clinical development of the STn-KLH vaccine (Theratope). Clin. Breast Cancer 2003, 3(Suppl 4):S139-S143.
158. Parry A.L., Clemson N.A., Ellis J., Bernhard S.S., Davis B.G., Cameron N.R. 'Multicopy multivalent' glycopolymer-stabilized gold nanoparticles as potential synthetic cancer vaccines. J. Am. Chem. Soc. 2013, 135:9362-9365.
159. Kaiser A., Gaidzik N., Westerlind U., Kowalczyk D., Hobel A., Schmitt E., Kunz H. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. Angew. Chem. Int. Ed Engl. 2009, 48:7551-7555.
160. Westerlind U., Hobel A., Gaidzik N., Schmitt E., Kunz H. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. Engl. 2008, 47:7551-7556.
161. Cai H., Huang Z.H., Shi L., Zhao Y.F., Kunz H., Li Y.M. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Chemistry 2011, 17:6396-6406.
162. Abdel-Aal A.B., Lakshminarayanan V., Thompson P., Supekar N., Bradley J.M., Wolfert M.A., Cohen P.A., Gendler S.J., Boons G.J. Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist. Chembiochem 2014, 15:1508-1513.
163. Schultz M.J., Swindall A.F., Bellis S.L. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metastasis Rev. 2012, 31:501-518.
164. Hsu C.C., Lin T.W., Chang W.W., Wu C.Y., Lo W.H., Wang P.H., Tsai Y.C. Soyasaponin-I-modified invasive behavior of cancer by changing cell surface sialic acids. Gynecol. Oncol. 2005, 96:415-422.
165. Chiang C.H., Wang C.H., Chang H.C., More S.V., Li W.S., Hung W.C. A novel sialyltransferase inhibitor AL10 suppresses invasion and metastasis of lung cancer cells by inhibiting integrin-mediated signaling. J. Cell. Physiol. 2010, 223:492-499.
166. Chang W.W., Yu C.Y., Lin T.W., Wang P.H., Tsai Y.C. Soyasaponin I decreases the expression of alpha2,3-linked sialic acid on the cell surface and suppresses the metastatic potential of B16F10 melanoma cells. Biochem. Biophys. Res. Commun. 2006, 341:614-619.
167. Becker D.J., Lowe J.B. Fucose: biosynthesis and biological function in mammals. Glycobiology 2003, 13:41R-53R.
168. Macauley M.S., Arlian B.M., Rillahan C.D., Pang P.C., Bortell N., Marcondes M.C., Haslam S.M., Dell A., Paulson J.C. Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases. J. Biol. Chem. 2014, 289:35149-35158.
169. Rillahan C.D., Antonopoulos A., Lefort C.T., Sonon R., Azadi P., Ley K., Dell A., Haslam S.M., Paulson J.C. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat. Chem. Biol. 2012, 8:661-668.
170. Ernst B., Magnani J.L. From carbohydrate leads to glycomimetic drugs. Nat. Rev. Drug Discov. 2009, 8:661-677.
171. Marathe D.D., Buffone A., Chandrasekaran E.V., Xue J., Locke R.D., Nasirikenari M., Lau J.T., Matta K.L., Neelamegham S. Fluorinated per-acetylated GalNAc metabolically alters glycan structures on leukocyte PSGL-1 and reduces cell binding to selectins. Blood 2010, 115:1303-1312.
172. Sorensen A.L., Reis C.A., Tarp M.A., Mandel U., Ramachandran K., Sankaranarayanan V., Schwientek T., Graham R., Taylor-Papadimitriou J., Hollingsworth M.A., Burchell J., Clausen H. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance. Glycobiology 2006, 16:96-107.